Skip to content

Intranasal Dexmedetomidine in Children Undergoing Adenotonsillectomy Suffering From Mild Upper Respiratory Tract Infection

The Effect of Intranasal Dexmedetomidine Premedication in Children Undergoing Adenotonsillectomy Suffering From Recent Mild Upper Respiratory Tract Infection

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05639777
Enrollment
70
Registered
2022-12-06
Start date
2022-12-06
Completion date
2023-05-15
Last updated
2022-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenotonsillectomy, Dexmedetomidine, Respiratory Tract Infections

Brief summary

The purpose of this study is to detect the efficacy of intranasal dexmedetomidine as a premedication to general anesthesia in pediatric patients with respiratory comorbidities undergoing adenotonsillectomy.

Detailed description

Respiratory comorbidities are associated with an increased incidence of peri-operative respiratory adverse effects (PRAE). Upper and lower respiratory infections, as well as asthma, are common in children who are scheduled for adenotonsillectomy. When compared to healthy children, children with respiratory ailments have a three-fold increase in PRAEs.

Interventions

DRUGDexmedetomidine group

That will receive intranasal dexmedetomidine (1.5mcg/kg)

OTHERcontrol group

That will receive the same volume of 2 ml of intranasal normal saline

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
3 Years to 10 Years
Healthy volunteers
Yes

Inclusion criteria

1. Children with recent mild URI or asthma. 2. aged from 3 to 10 years 3. ASA Physical Status II, 4. undergoing adenotonsillectomy

Exclusion criteria

1. Parental refusal of participation 2. Evidence of moderate to severe upper respiratory tract infection at time of presentation on the day of surgery 3. Lower respiratory tract infection 4. Congenital heart diseases 5. Known hypersensitivity to specific anesthetic agent 6. Liver or renal disease

Design outcomes

Primary

MeasureTime frameDescription
The incidence of peri-operative respiratory adverse effects (PRAE).From induction to emergence from general anesthesia.All PRAE and the time of occurrence (induction, maintenance or emergence) will be recorded.

Secondary

MeasureTime frameDescription
Sedating effects of this drug.15 and 30 min after sedationThe sedating effects will be measure using Ramsay sedation scale from 1 to 6 as 1 meaning anxious and agitated, restless, or both. and 6 meaning Unresponsive.
Ease of parental separation.15 and 30 min after sedationEvaluated using a four-point scale. from 1 to 4 as 1 meaning excellent and 4 for poor
Face mask acceptance.15 and 30 min after sedationEvaluated using a four-point scale. from 1 to 4 as 1 meaning excellent and 4 for poor
Hemodynamic stability15 and 30 min after sedationhypertension, tachycardia, bradycardia

Countries

Egypt

Contacts

Primary ContactEman A Azzam, M․B․B․CH
eman162092_pg@med.tanta.edu.eg0020103743150

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026